期刊文献+

减少生殖器疱疹复发激光相关十种不同新治疗及其方法学研究

Study of New Therapy Method to Decrease the Relapse of Genital Herpes with Laser
暂未订购
导出
摘要 目的探索研究自创减少生殖器疱疹(CH)复发的激光相关新治疗方法学。方法随机采用作者自拟的邱氏GH治疗方法,治疗组A组(A.T.G.H.Q)、B组(B.T.G.H.Q)、C组(C.T.G.H.Q)、D组(D.T.G.H.Q)、E组(E.T.G.H.Q)、F组(F.T.G.H_.Q)、G组(G.T.G.H.Q)、H组(H.T.G.H.Q)、I组(I.T.G.H.Q)、J组(J.T.G.H.Q),对照(单纯应用药物治疗)组K组(K.T.G.H.Q)等,共计11个不同的治疗(与对照)方法组,每组50例(共计550例)GH患者的治疗,并(经过7~14天治疗)于达到临床近期治愈1个月之后开始进行2~8年的远期效果随访观察。结果痊愈(未复发)比率分别为,治疗组A组24%、B组22%、C组32%、D组30%、E组36%、F组44%、G组42%、H组48%、I组60%、J组58%,对照组K组18%。以10个治疗组分别与对照绀比较,表明均有显著性差异,其中I组和J组效果最好、具有特别屁著性意义。结论激光配合药物治疗GH的远期效果相对最理想,有进一步研究的意义和推广直用之价值。 Objective To explore new therapy method to reduce relapse of genital herpes (GH) with laser. Methods 550 cases GH treated with Laser were randomly derided into 11 different groups ( each group 50 cases : group A ( A. T. GH. Q ) , B ( B. TGH. Q ) , C ( C. T. GH.Q), D (D. TGH. Q), E(E.T. GH.Q), F (F. TGH. Q), G (G.T. GH.Q), H (H.T. GH.Q), I (1. T. GH.Q), J (J.T. GH.Q) and K group ( K. T. GH. Q). All of cases started with 2 - 8 years of follow - up after clinical short - term being cured. Results Cure rate were: A 24% , B 22% , C 32%, D 30% , E 36% , F 448% , G 42% , H 48%, I 60% , J 58%, K 18%. Conclusion GH treated by Laser auompanied by drug has good and ideal long-term effectiveness, worthwhile for further study and popularized clinical application.
作者 邱德明
出处 《医学研究杂志》 2008年第10期111-113,共3页 Journal of Medical Research
关键词 新治疗方法 生殖器疱疹 复发 激光相关治疗 New method Genital herpes Relapse Laser/ treatment
  • 相关文献

参考文献3

  • 1邱德明.激光治疗生殖器疱疹远期效果随访比较研[J].中华医师论坛杂志,2007,2(3):14-16.
  • 2邱德明.生殖器疱疹激光经络穴位疗法远期效果随访研究[J].中华医学临床杂志,2007,5(6):18-20.
  • 3马慧军,朱文元.频发性生殖器疱疹的治疗研究进展[J].临床皮肤科杂志,2005,34(2):130-132. 被引量:28

二级参考文献19

  • 1Reyes M, Shaik NS, Graber JM, et al. Acyclovir-resistant genital herpes among persons attending sexually transmitted disease and human immunodeficiency virus clinics [J]. Arch Intern Med,2003, 163(1): 76-80.
  • 2Gershengorn HB, Darby G, Blower SM. Predicting the emergence of drug-resistant HSV-2: new predictions[J]. BMC Infect Dis,2003, 3(1): 1.
  • 3Pechere M, Wunderli W, Trellu-Toutous L, et al. Treatment of acyclovir-resistant herpetic ulceration with topical foscarnet and antiviral sensitivity analysis[J]. Dermatology, 1998, 197(3): 278-280.
  • 4Chilukuri S, Rosen T. Management of acyclovir-resistant herpes simplex virus[J]. Dermatol Clin, 2003, 21(2): 311-320.
  • 5Tyring SK, Baker D, Snowden W. Valacyclovir for herpes simplex virus infection: long-term safety and sustained efficacy after 20 years' experience with acyclovir[J]. J Infect Dis, 2002, 186(Suppl 1): S40-46.
  • 6Bodsworth NJ, Crooks RJ, Borelli S, et al. Valaciclovir versus aciclovir in patient initiated treatment of recurrent genital herpes: a randomised, double blind clinical trial. International Valaciclovir HSV Study Group[J]. Genitourin Med, 1997, 73(2):110-116.
  • 7Mertz GJ, Loveless MO, Levin MJ, et al. Oral famciclovir for suppression of recurrent genital herpes simplex virus infection in women. A multicenter, double-blind, placebo-controlled trial.Collaborative Famciclovir Genital Herpes Research Group[J].Arch Intern Med, 1997, 157(3): 343-349.
  • 8Kroon S, Petersen CS, Andersen LP, et al. Long-term suppression of severe recurrent genital herpes simplex infections with oral acyclovir: a dose-titration study[J]. Genitourin Med, 1990,66(2): 101-104.
  • 9Kinghorn Gl, Fiddian AP. Prevention of lesion development in recurrent genital herpes with oral valaciclovir [J]. J Eur Acad Dermatol Venereol, 1995, 5(Suppl 1): S162.
  • 10Leone PA, Trottier S, Miller JM. Valacyclovir for episodic treatment of genital herpes: a shorter 3-day treatment course compared with 5-day treatment[J]. Clin Infect Dis, 2002, 34(7):958-962.

共引文献27

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部